Health ❯Healthcare ❯Pharmaceuticals ❯Drug Development

Clinical Trials

Roivant’s Brepocitinib Succeeds in 52-Week Dermatomyositis Phase 3 as Companies Target 2026 FDA Filing

The TYK2/JAK1 pill delivered steroid-sparing benefits that underpin a planned early‑2026 FDA submission.

AstraZeneca’s Fasenra Misses Primary Endpoint in COPD Phase III Trial

Sanofi’s Amlitelimab Meets Phase 3 Goals in Eczema as Shares Fall on Tepid Efficacy

AstraZeneca’s Baxdrostat Lowers Blood Pressure in Phase III, Setting Up 2025 Filings

FDA Approves Ionis’ Dawnzera to Prevent Hereditary Angioedema Attacks

Viking’s Oral Obesity Pill Shows Strong Weight Loss but High Dropouts, Triggering Stock Rout

Wegovy Wins FDA Nod for MASH as Novo Rolls Out $499 Cash Ozempic in U.S.

FDA Approves First New Fibromyalgia Treatment in 15 Years

GLP-1 Agonists Linked to Small Rise in Diabetic Retinopathy and Rare Optic-Nerve Events

King’s Spin-out Targets Human Trials for Oral Cancer Drug After Promising Mouse Results

Eli Lilly’s Oral Obesity Pill Triggers Stock Slide After Modest Weight-Loss Results

Novel Alzheimer’s Antibody Moves to Phase III After 90% Plaque Clearance

Celcuity’s Gedatolisib Combos Yield Up to 76% Progression-Free Survival Gain in Phase 3 Trial

EMA Recommends Restricted Approval for Eli Lilly’s Alzheimer’s Drug Kisunla

FDA Rejects Replimune’s RP1 Melanoma Immunotherapy

Nature Study Shows Gut Bacterium YB328 Boosts Cancer Immunotherapy

FDA Clears MT-125 for First Human Trials in Treatment-Resistant Glioblastoma

Novo Nordisk’s Amycretin Achieves Up to 24% Weight Loss as It Advances to Phase 3

Eli Lilly’s Oral GLP-1 Pill Matches Injectables in Weight and Blood Sugar Control

Eli Lilly to Acquire Verve Therapeutics as Gene-Editing Trial Begins